Sanofi and Regeneron Receive FDA Approval for Dupixent in Pediatric Prurigo Nodularis

Sanofi and Regeneron today announced that the FDA has approved Dupixent (dupilumab) for the treatment of adolescents 12 to 17 years of age with moderate-to-severe prurigo nodularis. This approval expands Dupixent's PN indication to include adolescents, providing younger patients with a biologic treatment option for this debilitating skin disease. In clinical trials, Dupixent demonstrated significant improvements in itch and skin lesions in adolescent patients. This approval reinforces Dupixent's growing portfolio of skin disease indications.